Evidence map›Paper›PMID 24619848›Full record

ReviewMovement disorders : official journal of the Movement Disorder Society2014

Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.

Daniela Berg, Ronald B Postuma, Bastiaan Bloem, Piu Chan, Bruno Dubois, Thomas Gasser, Christopher G Goetz, Glenda M Halliday, John Hardy, Anthony E Lang and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Movement disorders : official journal of the Movement Disorder Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 231 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
231citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

231 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Virtual reality for rehabilitation in Parkinson's disease.The Cochrane database of systematic reviews · 2016
    Pooled it
  6. Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial.Movement disorders : official journal of the Movement Disorder Society · 2022
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Species-dependent activities of the PINK1-parkin axis.Translational neurodegeneration · 2026
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

171 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Daniela BergDepartment of Neurodegeneration, Hertie Institute for Clinical Brain Research and German Center of Neurodegenerative Diseases, Tuebingen, Germany.
Ronald B Postuma
Bastiaan Bloem
Piu Chan
Bruno Dubois
Thomas Gasser
Christopher G Goetz
Glenda M Halliday
John Hardy
Anthony E Lang
Irene Litvan
Kenneth Marek
José Obeso
Wolfgang Oertel
C Warren Olanow
Werner Poewe
Matthew Stern
Günther Deuschl

Funding

Medical Research Council G0701075Medical Research Council MC_G1000735Wellcome Trust 089698
6 · The paper itself

Abstract

With advances in knowledge disease, boundaries may change. Occasionally, these changes are of such a magnitude that they require redefinition of the disease. In recognition of the profound changes in our understanding of Parkinson's disease (PD), the International Parkinson and Movement Disorders Society (MDS) commissioned a task force to consider a redefinition of PD. This review is a discussion article, intended as the introductory statement of the task force. Several critical issues were identified that challenge current PD definitions. First, new findings challenge the central role of the classical pathologic criteria as the arbiter of diagnosis, notably genetic cases without synuclein deposition, the high prevalence of incidental Lewy body (LB) deposition, and the nonmotor prodrome of PD. It remains unclear, however, whether these challenges merit a change in the pathologic gold standard, especially considering the limitations of alternate gold standards. Second, the increasing recognition of dementia in PD challenges the distinction between diffuse LB disease and PD. Consideration might be given to removing dementia as an exclusion criterion for PD diagnosis. Third, there is increasing recognition of disease heterogeneity, suggesting that PD subtypes should be formally identified; however, current subtype classifications may not be sufficiently robust to warrant formal delineation. Fourth, the recognition of a nonmotor prodrome of PD requires that new diagnostic criteria for early-stage and prodromal PD should be created; here, essential features of these criteria are proposed. Finally, there is a need to create new MDS diagnostic criteria that take these changes in disease definition into consideration.

Indexed as

Advisory CommitteesDiagnostic and Statistical Manual of Mental DisordersHumansNeuropsychological TestsParkinson Diseasedisease heterogeneitygold standardMDS diagnostic criterianonmotor prodromeredefinition of PDsubtypes

Identifiers

PMID24619848
PMCPMC4204150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.